BioLine RX (Israel) Performance
| BLRX Stock | ILS 7.10 0.40 5.33% |
The firm shows a Beta (market volatility) of 0.37, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioLine RX's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioLine RX is expected to be smaller as well. At this point, BioLine RX has a negative expected return of -1.7%. Please make sure to confirm BioLine RX's total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if BioLine RX performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BioLine RX has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 16.8 M | |
| Total Cashflows From Investing Activities | -38.2 M |
BioLine |
BioLine RX Relative Risk vs. Return Landscape
If you would invest 1,700 in BioLine RX on September 12, 2024 and sell it today you would lose (990.00) from holding BioLine RX or give up 58.24% of portfolio value over 90 days. BioLine RX is generating negative expected returns and assumes 6.2567% volatility on return distribution over the 90 days horizon. Simply put, 55% of stocks are less volatile than BioLine, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BioLine RX Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioLine RX's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioLine RX, and traders can use it to determine the average amount a BioLine RX's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2723
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BLRX |
Estimated Market Risk
| 6.26 actual daily | 55 55% of assets are less volatile |
Expected Return
| -1.7 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.27 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioLine RX is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioLine RX by adding BioLine RX to a well-diversified portfolio.
BioLine RX Fundamentals Growth
BioLine Stock prices reflect investors' perceptions of the future prospects and financial health of BioLine RX, and BioLine RX fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioLine Stock performance.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | (13.02 M) | |||
| Shares Outstanding | 922.87 M | |||
| Price To Book | 0.77 X | |||
| EBITDA | (25.37 M) | |||
| Cash And Equivalents | 40.61 M | |||
| Cash Per Share | 0.28 X | |||
| Total Debt | 10.69 M | |||
| Debt To Equity | 23.20 % | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (23.57 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 81.39 M | |||
| Retained Earnings | (163 M) | |||
| Current Asset | 46 M | |||
| Current Liabilities | 3 M | |||
About BioLine RX Performance
By analyzing BioLine RX's fundamental ratios, stakeholders can gain valuable insights into BioLine RX's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioLine RX has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioLine RX has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people.Things to note about BioLine RX performance evaluation
Checking the ongoing alerts about BioLine RX for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioLine RX help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioLine RX generated a negative expected return over the last 90 days | |
| BioLine RX has high historical volatility and very poor performance | |
| Net Loss for the year was (27.05 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| BioLine RX has accumulated about 40.61 M in cash with (23.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28. |
- Analyzing BioLine RX's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioLine RX's stock is overvalued or undervalued compared to its peers.
- Examining BioLine RX's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioLine RX's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioLine RX's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioLine RX's stock. These opinions can provide insight into BioLine RX's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioLine Stock analysis
When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |